2026年波士顿马拉松前夕，耐克的橱窗广告把自己送上了舆论的火线。那句“Runners welcome. Walkers tolerated”——欢迎跑者，容忍步行者——以红底大字占据着纽伯里街门店的整个橱窗，距离波士顿马拉松终点线仅一个街区。 评论家们将其贴上"配速羞辱"、排他性、甚至是对受伤选手、适应性运动员和首次参赛者的轻蔑。耐克迅速做出回应，撤下了标识，并承认自己"做得不妥"。 耐克的危机公关话术不算新鲜，真正耐人寻味的是：这个曾以“冒犯式营销”屡战屡胜的体育巨头，这一次，为什么踢到了铁板？ 从“利器”到“暗器”：耐克的冒犯美学为何失灵 耐克的品牌基因里刻着“冲突”二字。从“Just Do It”这句充满战斗感的口号，到上世纪80年代聘用“坏小子”约翰·麦肯罗和查尔斯·巴克利——他们以傲慢、暴躁、不守规则的公众形象代言耐克——这家公司向来不回避站队、划线，甚至主动挑衅主流社会情绪。真正的巅峰时刻是2018年的科林·卡佩尼克广告。那位因国歌抗议而遭NFL封杀的争议四分卫，配以“Believe in something. Even if it means sacrificing everything.”的文案，在美国 政治极化的舆论场中炸开了锅。抵制者们焚烧耐克鞋，股价一度跳水。但仅仅数天后，耐克在线销售额增长31%，品牌市值反而创下历史新高。 营销学教授阿梅里克斯·里德对此有一句精辟总结：如果你足够清晰地代表某件事，你就不可避免地站在了另一件事的对立面。这种策略称为“中心化机制”——通过划定“我们”与“他们”的边界，来凝聚核心人群的身份认同。按照这一逻辑，“欢迎跑者，容忍步行者”并不令人意外。波士顿马拉松的门槛是全世界最严苛之一：约90%的参赛者须凭硬核成绩入围，男性资格标准高达2小时55分。在终点线旁的门店，向那些“破三”人群喊出“这是我们的主场”，似乎是耐克一以贯之的“冒犯美学”的又一次精准运用。 但现实迅速给出了否定的答案。首先，“容忍”一词自带权力关系——它暗示说话者处于高位，而接受者是低位。一位因脊髓囊肿而不得不采用跑走结合策略的波士顿马拉松选手罗宾·米肖，在Instagram上反讽道：“谢谢你‘容忍’我。”她拥有多次达标参赛的记录，却被一句广告文案置于“二等参与者”的屈辱位置。大量使用跑走结合策略的跑者也愤怒质问：难道我因为步行休息一下，就成了被“...
Arteris, Inc. has announced that its semiconductor technology has been adopted by Li Auto for their intelligent vehicles, specifically incorporating the technology into the company's autonomous driving systems-on-chip (SoCs) in the new L9 Livis high-tech SUV. This deployment marks a significant step in the integration of AI capabilities within the automotive sector, supporting Li Auto's high-perfo...
Arteris, Inc. has announced that its semiconductor technology has been adopted by Li Auto for their intelligent vehicles, specifically incorporating the technology into the company's autonomous driving systems-on-chip (SoCs) in the new L9 Livis high-tech SUV. This deployment marks a significant step in the integration of AI capabilities within the automotive sector, supporting Li Auto's high-performance computing needs while meeting energy efficiency and safety requirements. Arteris FlexNoC network-on-chip (NoC) IP and Magillem software play a crucial role in optimizing data movement and integrating various processing elements to balance performance and power efficiency in Li Auto's vehicles. This collaboration highlights the growing importance of semiconductor solutions in the advancement of smart vehicle technology. Elsewhere in the market, Skyverse Technology was trading firmly up 17.4% and ending the day at CN¥258.94. In the meantime, Phison Electronics trailed, down 8.3% to end the day at NT$2,260.00. AMD's strategic deals and AI-driven tech could rapidly boost its market share click to explore the full narrative on its growth trajectory. Don't miss our Market Insights article, 'China's Next Winners Have Been Chosen,' exploring China's strategic focus on AI and semiconductor advancements—time to get ahead in this competitive space! Best AI Chip Stocks Micron Technology ended the day at $698.74 up 2.5%. NVIDIA settled at $220.61 down 0.8%. Two days ago, Dell introduced a locally deployable AI solution with NVIDIA, enhancing agentic AI workflows without cloud constraints. Advanced Micro Devices finished trading at $414.05 down 1.6%. Turning Ideas Into Actions This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of...
Bristol-Myers Squibb ( BMY ) is rolling out Anthropic ’s ( ANTHRO ) flagship Claude AI platform to more than 30,000 employees, expanding its use of artificial intelligence and AI agents across research, clinical development, and corporate operations. The collaboration signals a meaningful evolution in how BMS deploys AI, moving beyond conversational tools that have defined the first wave of enterp...
Bristol-Myers Squibb ( BMY ) is rolling out Anthropic ’s ( ANTHRO ) flagship Claude AI platform to more than 30,000 employees, expanding its use of artificial intelligence and AI agents across research, clinical development, and corporate operations. The collaboration signals a meaningful evolution in how BMS deploys AI, moving beyond conversational tools that have defined the first wave of enterprise adoption, toward agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations. In addition, Bristol-Myers said it is using Claude Code, Anthropic’s coding tool, to speed up its software and AI development. The company also said it is evaluating the use of Claude AI agents in areas including research, drug development, and commercial and medical affairs. "By giving employees access to Claude’s agentic capabilities — connected to thousands of data sources across the company — BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time,” said Eric Kauderer-Abrams , Head of Life Sciences, Anthropic. Anthropic's rival OpenAI ( OPENAI ) has also struck partnerships with key players in the sector. It announced an agreement with biotech giant Moderna ( MRNA ) to automate business processes in 2024 and landed a deal with Wegovy maker Novo Nordisk ( NVO ) to speed up drug discovery earlier this year. More on Bristol-Myers Squibb Company, Anthropic Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing Bristol-Myers Squibb Company 2026 Q1 - Results - Earnings Call Presentation Regulators delay cyber tests for banks to give time to strengthen systems against AI threat - report Google releases Gemini 3.5 Flash; surpasses G...
Medline ( MDLN ) said certain shareholders affiliated with Blackstone ( BX ), Hellman & Friedman, and a subsidiary of the Abu Dhabi Investment Authority are launching a public offering of 60M Medline shares. The selling shareholders also plan to give underwriters the option to buy up to an additional 9M shares within 30 days. Goldman Sachs & Co. LLC ( GS ), Morgan Stanley ( MS ), BofA Securities (...
Medline ( MDLN ) said certain shareholders affiliated with Blackstone ( BX ), Hellman & Friedman, and a subsidiary of the Abu Dhabi Investment Authority are launching a public offering of 60M Medline shares. The selling shareholders also plan to give underwriters the option to buy up to an additional 9M shares within 30 days. Goldman Sachs & Co. LLC ( GS ), Morgan Stanley ( MS ), BofA Securities ( BAC ), and J.P. Morgan ( JPM ) are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets is acting as co-manager for the proposed offering. MDLN shares fell -3.5% premarket to $36.37. More on Medline Inc. Medline Inc. 2026 Q1 - Results - Earnings Call Presentation Medline Inc. (MDLN) Q1 2026 Earnings Call Transcript Medline: A Lack Of Compelling Risk-Reward Makes Me Cautious Medline raises 2026 organic sales growth outlook to 8.5%-9.5% while holding $3.5B-$3.6B adjusted EBITDA amid tariff and fuel uncertainty Goldman Sachs cuts IPO forecast; biggest IPOs since 2025 ranked by market cap
Stock Yards Bancorp ( SYBT ) declares $0.32/share quarterly dividend , in line with previous. Forward yield 1.82% Payable July 1; for shareholders of record June 15; ex-div June 15. See SYBT Dividend Scorecard, Yield Chart, & Dividend Growth. More on Stock Yards Bancorp Stock Yards Bancorp: Acquisition Will Boost Earnings Seeking Alpha’s Quant Rating on Stock Yards Bancorp Historical earnings data...
Stock Yards Bancorp ( SYBT ) declares $0.32/share quarterly dividend , in line with previous. Forward yield 1.82% Payable July 1; for shareholders of record June 15; ex-div June 15. See SYBT Dividend Scorecard, Yield Chart, & Dividend Growth. More on Stock Yards Bancorp Stock Yards Bancorp: Acquisition Will Boost Earnings Seeking Alpha’s Quant Rating on Stock Yards Bancorp Historical earnings data for Stock Yards Bancorp Dividend scorecard for Stock Yards Bancorp Financial information for Stock Yards Bancorp
Keir Starmer has announced an extension to the temporary 5p cut in fuel duty, as widely expected, telling the Commons it was a necessary response to cost-of-living pressures. Before a wider package of measures due to be announced by Rachel Reeves, the chancellor, on Thursday, Starmer used prime minister’s questions to announce the extended freeze and a vehicle tax break for the haulage industry. A...
Keir Starmer has announced an extension to the temporary 5p cut in fuel duty, as widely expected, telling the Commons it was a necessary response to cost-of-living pressures. Before a wider package of measures due to be announced by Rachel Reeves, the chancellor, on Thursday, Starmer used prime minister’s questions to announce the extended freeze and a vehicle tax break for the haulage industry. At the last budget, Reeves announced she would freeze fuel duty for nine months but that she would end a temporary 5p cut, first announced by Rishi Sunak in 2022 after Russia’s full-scale invasion of Ukraine, beginning in September. Asked by the Labour MP Kirsteen Sullivan about whether the government could do more to help with cost-of-living pressures, Starmer replied: “There is more that we can do, and I can announce today that we are giving our hauliers a 12-month vehicle tax holiday, helping to keep prices down, and we are backing drivers by extending the freeze in fuel duty for the rest of the year. “This is possible because of the decisions taken by the chancellor, making us the fastest-growing economy in the G7. She will set out further action tomorrow.” Referring to increased fuel prices caused by the US-Israeli attack on Iran, Starmer added: “This is not our war, but while the parties opposite wanted to jump into it, Labour will always protect working people.” Responding for the Conservatives, Kemi Badenoch sought to claim credit for the decision, saying it was a U-turn caused by her pressure. Starmer rejected this, saying it was only because of what had happened with Iran, adding: “I know the leader of the opposition likes to claim responsibility for things that have got literally nothing to do with her. In her mind, she won Eurovision on Saturday and scored the winning goal in the FA Cup final.” A Treasury announcement, released as Starmer spoke, said that by the end of 2026 the freeze of fuel duty would have saved the average driver £120 over two years, while the...
Key Points Amazon is a stone's throw away from reaching $3 trillion. Broadcom and Taiwan Semiconductor are thriving amid the AI build-out. Meta's stock is dramatically undervalued, and a reasonable valuation could result in a $3 trillion market cap. These 10 stocks could mint the next wave of millionaires › Only four companies have a market value of $3 trillion or more. However, by the end of 2027...
Key Points Amazon is a stone's throw away from reaching $3 trillion. Broadcom and Taiwan Semiconductor are thriving amid the AI build-out. Meta's stock is dramatically undervalued, and a reasonable valuation could result in a $3 trillion market cap. These 10 stocks could mint the next wave of millionaires › Only four companies have a market value of $3 trillion or more. However, by the end of 2027, I think four other companies will join this exclusive club. One of these stocks is a no-brainer, but the other three will need to make some noise to reach a $3 trillion market cap by the time 2027 ends. The four stocks I think can reach this level are Amazon(NASDAQ: AMZN), Taiwan Semiconductor Manufacturing(NYSE: TSM), Broadcom(NASDAQ: AVGO), and Meta Platforms(NASDAQ: META). All four of these stocks are heavy competitors in the artificial intelligence (AI) build-out, and I think they could make for genius investments. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Amazon Amazon is about the easiest pick for this list. It currently has a $2.8 trillion market cap, so reaching $3 trillion should occur this year, let alone 2027. While Amazon is commonly thought of as a commerce investment, the reality is that its Amazon Web Services (AWS) cloud computing segment is driving a lot of its earnings growth. AWS' first quarter was its best quarter in nearly four years, and if it can keep that pace up, the company should easily reach $3 trillion within a few months and be well past the $3 trillion mark by the end of 2027. Taiwan Semiconductor Now is where things get a bit more interesting. Currently, Taiwan Semiconductor is a $2 trillion company, so it needs to rise about 50% to gain entry to the $3 trillion club. That's no easy feat, but with major chip demand stemming from increased AI spending, I think it's p...
Over the last 7 days, the United States market has experienced a 1.0% drop, yet it remains up by 23% over the past year with earnings projected to grow by 17% annually. In this context, identifying growth companies with strong insider ownership can be an effective strategy as these firms often demonstrate commitment and confidence from those who know them best. Top 10 Growth Companies With High In...
Over the last 7 days, the United States market has experienced a 1.0% drop, yet it remains up by 23% over the past year with earnings projected to grow by 17% annually. In this context, identifying growth companies with strong insider ownership can be an effective strategy as these firms often demonstrate commitment and confidence from those who know them best. Top 10 Growth Companies With High Insider Ownership In The United States Name Insider Ownership Earnings Growth Uxin (UXIN) 33.4% 74.1% Upstart Holdings (UPST) 12.8% 58.1% Laird Superfood (LSF) 16.1% 115.9% Karman Holdings (KRMN) 15.7% 52.6% FirstSun Capital Bancorp (FSUN) 21% 54.2% Figure Technology Solutions (FIGR) 25% 54.1% Duos Technologies Group (DUOT) 11.2% 158.4% Corcept Therapeutics (CORT) 11.8% 48.7% Astera Labs (ALAB) 10.7% 31.5% AppLovin (APP) 27.4% 21.6% Click here to see the full list of 181 stocks from our Fast Growing US Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: AppFolio, Inc. offers a cloud-based platform tailored for the real estate industry in the United States and has a market cap of approximately $5.58 billion. Operations: The company generates revenue of $995.33 million from its cloud-based business management software and Value+ platforms for the real estate sector in the United States. Insider Ownership: 27.2% Revenue Growth Forecast: 15% p.a. AppFolio's earnings are forecast to grow at 19.9% annually, outpacing the US market. Despite a decline in profit margins from 23.9% to 15.3%, it trades at a significant discount to its estimated fair value and analysts expect a price increase of 43.4%. Recent leadership changes with Kyle Triplett as Chief Product Officer may enhance product innovation, while raised revenue guidance for 2026 supports its growth trajectory, projecting US$1.11 billion to US$1.125 billion in sales. APPF Ownership Breakdown as at May 2026 Simply...
Supatman/iStock via Getty Images Co-authored with Beyond Saving You are preparing for retirement, or maybe you have recently retired, and you have decided that you want to manage your own investments. Congratulations! You have already taken two steps that a very large number of people never take: you saved up capital, and you took charge of it. Too many people just go through life crossing their f...
Supatman/iStock via Getty Images Co-authored with Beyond Saving You are preparing for retirement, or maybe you have recently retired, and you have decided that you want to manage your own investments. Congratulations! You have already taken two steps that a very large number of people never take: you saved up capital, and you took charge of it. Too many people just go through life crossing their fingers and hoping everything will work out. Now what? Every day, I talk to investors who treat the stock market like a lottery ticket. They scour the market looking to make quick trades, hoping that they can buy something that will become popular and then sell it before it becomes unpopular. There are several strategies that attempt to achieve this. Some focus on technical trading signals that attempt to be ahead of the popularity curve. Others focus on trying to predict news cycles, trading in and out of sectors as their popularity increases or decreases based on what's happening in the news cycle. Others will buy ideas that they think might become the next big thing, hoping to find the next Nvidia ( NVDA ) to offset the fizzles like Beyond Meat ( BYND ). All of these strategies revolve around the idea of buying a stock to sell it at some point in the future, hopefully at a higher price. There are many ways to make money investing in the stock market, and I encourage you to find a strategy that works for you. Our strategy is different from all of those above. Our strategy isn't to buy things because we believe we will find some sucker willing to pay a price higher than we would be willing to pay. Our strategy isn't to spend our later years selling off the shares we worked so hard to accumulate. We are income investors. Our strategy is to turn our portfolios into a cash-producing business. A business that produces enough cash to meet our needs in retirement, and retain enough to reinvest for future growth. Today, let's address the top three reasons why we are income investo...
Beijing banned Nvidia’s gaming chip to reduce dependence on downgraded products and support local chipmakers such as Huawei and Cambricon. In this photo illustration, a Nvidia logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images) Loading... Loading... Loading... Loading... Loading... Loading....
Beijing banned Nvidia’s gaming chip to reduce dependence on downgraded products and support local chipmakers such as Huawei and Cambricon. In this photo illustration, a Nvidia logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images) Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Loading... Nvidia’s RTX 5090D V2 chip was added to the list of banned products by Beijing during the Trump-Xi Summit. Nvidia’s gaming chip joins the likes of its H200 and H20 AI chips, which are also restricted for use in China. KeyBanc said earlier this week that Nvidia’s H200 chips represent a $14 billion revenue opportunity in China. As investors buckle up for U.S. chip giant Nvidia (NVDA)'s first-quarter results after the closing bell on Wednesday, a Financial Times report said the company’s China-specific gaming chip was added to a list of banned commodities by Beijing during the Trump-Xi summit. The FT report said Nvidia’s RTX 5090D V2 chip, whose architecture is based on the company’s flagship Blackwell chips and complies with U.S. export controls, was added to the banned list last week as part of Beijing’s efforts to reduce dependency on downgraded Nvidia products and support local chipmakers like Huawei and Cambricon. Read Next Loading... Loading... Nvidia’s gaming chip joins the likes of its H200 and H20 AI chips, which are also restricted for use in China, to prevent U.S. firms from tapping into the lucrative Chinese market. Huang’s Commentary On China Is Highly Anticipated The report comes as Wall Street prepares for CEO Jensen Huang’s comments on his trip to China, the hottest topic to be discussed during the earnings call, and whether the company struck any deals. Huang was the last-minute addition to U.S. President Donald Trump’s entourage for the Beijing sum...
Upgrade Now This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below. Upgrade Now See Benefits Already have an account? Log in here. Before you consider Sandisk, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis....
Upgrade Now This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below. Upgrade Now See Benefits Already have an account? Log in here. Before you consider Sandisk, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandisk wasn't on the list. While Sandisk currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here
Mirum Pharmaceuticals NASDAQ: MIRM is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum recently reported its Q1 2026 earnings, headlined by 43% year-over-year (YOY) revenue growth. In 2025, the company reported revenue of $521.3 million, up 54%, with its lead drug Livmarli responsible for $...
Mirum Pharmaceuticals NASDAQ: MIRM is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum recently reported its Q1 2026 earnings, headlined by 43% year-over-year (YOY) revenue growth. In 2025, the company reported revenue of $521.3 million, up 54%, with its lead drug Livmarli responsible for $360 million, a 69% YOY increase. Mirum has two other FDA-approved therapies—Cholbam for bile-acid synthesis disorders, and Ctexli for cerebrotendinous xanthomatosis, a rare genetic bile acid metabolism disorder. Get Mirum Pharmaceuticals alerts: Sign Up The company also raised its full-year revenue guidance to a range of $660 million to $680 million. At the midpoint, that would be a YOY increase of 26%. However, since the earnings report, MIRM is down about 12% despite bullish analyst sentiment. What Makes Mirum a Compelling Speculative Play? Mirum Pharmaceuticals Today MIRM Mirum Pharmaceuticals $96.62 +0.98 (+1.02%) 52-Week Range $42.89 ▼ $114.99 Price Target $137.08 Add to Watchlist Mirum's commercial story is unusual for a company that is not profitable: it already has three FDA-approved drugs generating real, growing revenue. As noted above, Livmarli remains the primary growth engine, with Q1 2026 net product sales of $159.9 million representing robust sequential momentum. Livmarli is currently in a late-stage trial that could expand the drug’s label to include Alagille Syndrome. Topline data for Phase 3 is scheduled for December. Cholbam and Ctexli provide a revenue floor that single-asset biotechs don't have. The pipeline adds additional future revenue opportunities: Volixibat is in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), two conditions with significant unmet need and sizable patient populations. Brelovitug targets chronic hepatitis delta, and zilurgisertib is already under FDA regulatory review for fibro...